Cost Analysis of Treatment Success to Achieve a Clinically Relevant Composite Endpoint for Patients With Type-2 Diabetes on Liraglutide or Other Antidiabetic Therapies in a Chinese Setting
Value in Health- United Kingdom
doi 10.1016/j.jval.2013.03.802
Full Text
Abstract
Available in
Date
May 1, 2013
Authors
Publisher
Elsevier BV